

# **2017 Middle East Tumor Marker Diagnostics Market: Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities**

<https://marketpublishers.com/r/2960875FA43EN.html>

Date: February 2017

Pages: 530

Price: US\$ 8,865.00 (Single User License)

ID: 2960875FA43EN

## **Abstracts**

This new 11-country report from VPGMarketResearch.com is available by country, market segment, section, or individual test.

This report is designed to assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding cancer diagnostic testing market, in evaluating emerging opportunities and developing effective business strategies during the next five years.

The report provides granular market segmentation analysis and forecasts for over 40 tumor markers; profiles leading suppliers and recent market entrants with innovative technologies and products; reviews current and emerging assays; reviews current instrumentation; evaluates emerging technologies; and offers specific opportunities and growth strategies for suppliers.

## **Rationale**

The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer

therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide.

## **Country Analyses**

Bahrain, Iran, Iraq, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, United Arab Emirates

## **Business Opportunities and Strategic Recommendations**

Specific new product development opportunities with potentially significant market appeal during the next five years.

Design criteria for new products.

Alternative market penetration strategies.

Potential market entry barriers and risks.

## **Over 200 Current and Emerging Cancer Diagnostic Tests**

Oncogenes - Biochemical Markers - Growth Factors - Colony Stimulating Factors - Hormones - Immunohistochemical Stains - Lymphokines

ACTH, AFP, Beta-2 Microglobulin, CA 15-3/27.29, CA 19-9, CA 125, Calcitonin, Cathepsin, CEA, Chromogranin, Colon-Specific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG, Insulin, Interferons, Interleukins, Lymphocyte Subtyping, Neuron-Specific Enolase, Nucleolar, Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone, Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S-100 Protein, Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin, Tissue Polypeptide Antigen, and others.

## **Instrumentation Review**

Analysis of major molecular diagnostic and immunodiagnostic analyzers used for cancer testing, including their operating characteristics, features and selling

prices.

## **Technology Assessment**

Assessment of latest technologies and their potential applications for cancer diagnostic testing.

Review of competing/complementing technologies.

Companies, universities and research centers developing new cancer diagnostic tests and detection technologies.

## **Competitive Strategies**

Strategic assessments of major suppliers and start-up firms developing innovative cancer diagnostic technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D.

The companies analyzed in the report include:

Abbott

AdnaGen/Alere

Agilent Technologies

Applied Gene Technologies

Arca Biopharma

Beckman Coulter/Danaher

Becton Dickinson

Biomedical Diagnostics/Theradiag

bioMerieux

Bio-Rad

CellSearch

Cepheid

Correlogic Systems/Vermillion

Decode Genetics

Diadexus

DiaSorin

Eiken Chemical

Elitech Group

Enterix/Clinical Genomics

Enzo Biochem

Epigenomics

Exact Sciences

Fujirebio

Guided Therapeutics

Hologic/Gen-Probe

Kreatech/Leica

Kyowa Medex

Mackay Life Sciences

Myriad Genetics

OncoLab

Ortho-Clinical Diagnostics

Panacea Pharmaceuticals

Polartechinics

Polymedco

PreMD

Qiagen

Quest Diagnostics

Radiant Pharmaceuticals

Roche

Scienion

Sequenom

Siemens Healthcare

Takara Bio

Targeted Diagnostics & Therapeutics

Thermo Fisher/Affymetrix

Tosoh

Veridex

Wako Pure Chemicals

Wallac/PE

Zilla/Alere

Contains 530 pages and 50 tables

## Contents

### **I. INTRODUCTION**

### **II. MARKET OVERVIEW**

### **III. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES**

- A. Reagent Kits and Test Systems/Panels
- B. Instrumentation
- C. Computers, Software and Automation
- D. Auxiliary Products

### **IV. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS**

### **V. ALTERNATIVE MARKET PENETRATION STRATEGIES**

- A. Internal Development
- B. Collaborative Arrangements
- C. University Contracts
- D. Distribution Strategies

### **VI. POTENTIAL MARKET ENTRY BARRIERS AND RISKS**

- A. Market Maturity
- B. Cost Containment
- C. Competition
- D. Technological Edge and Limitations
- E. Patent Protection
- F. Regulatory Constraints
- G. Decentralized Testing Market Challenges

### **VII. MARKET AND TECHNOLOGY OVERVIEW**

- A. Cancer Statistics and Etiology
  - 1. BREAST CANCER
  - 2. LUNG CANCER
  - 3. COLON AND RECTUM CANCER
  - 4. PROSTATE CANCER

5. STOMACH CANCER

6. LEUKEMIA

7. LYMPHOMA

8. ORAL CANCER

9. SKIN CANCER

10. UTERINE CANCER

11. OVARIAN CANCER

12. BLADDER CANCER

**B. Major Current and Emerging Cancer Diagnostic Tests**

1. INTRODUCTION

2. TUMOR MARKER CLASSIFICATION

3. ACTH

4. ALPHA-FETOPROTEIN (AFP)

5. BETA-2 MICROGLOBULIN

6. CA 15-3/27.29

7. CA 19-9

8. CA-125

9. CALCITONIN

10. CARCINOEMBRYONIC ANTIGEN (CEA)

11. ESTROGEN AND PROGESTERONE RECEPTORS

12. FERRITIN

13. GASTRIN

14. HUMAN CHORIONIC GONADOTROPIN (HCG)

15. INSULIN

16. NSE

17. OCCULT BLOOD

18. PAP SMEAR/HPV

19. PROSTATIC ACID PHOSPHATASE (PAP)

20. PROSTATE-SPECIFIC ANTIGEN (PSA)

21. SQUAMOUS CELL CARCINOMA ANTIGEN (SCC)

22. T AND B LYMPHOCYTES

23. TDT

24. THYROGLOBULIN

25. TISSUE POLYPEPTIDE ANTIGEN (TPA)

26. BIOCHEMICAL TUMOR MARKERS

27. ONCOGENES

Abl/abl-bcr

AIB1

BCL-2



BRCA1  
CD44  
C-fos  
C-myb  
C-myc  
CYP-17  
Erb-B  
HPC1  
N-myc  
P40  
P51  
P53  
PIK3CA  
PTI-1  
Ras  
Reg  
Sis  
Src

## 28. POLYPEPTIDE GROWTH FACTORS

Basic Fibroblast Growth Factor  
Beta-TGF  
Cachectin (TNT)  
Calmodulin  
ECFR  
Nerve Growth Factor (NGF)  
Epidermal Growth Factor (EGF)  
Ornithine Decarboxylase  
Transferrin  
Transforming Growth Factor-Alpha

## 29. ECTOPIC HORMONES

## 30. COLONY STIMULATING FACTORS

## 31. LYMPHOKINES

Alpha-Interferon  
B Cell Growth Factors  
B Cell Growth Factor (BCGF)  
Gamma-Interferon  
Interleukin-1 (IL-1)  
Macrophage Activating Factor

## 32. IMMUNOHISTOCHEMICAL STAINS

### 33. EMERGING TUMOR MARKERS

N-Acetylglucosamine  
Actin  
Alpha-Actin  
Antineuronal Antibodies  
7B2  
B72.3  
Bax  
BCD-F9  
BLCA-4  
Blood Group Antigens A,B,H  
CA  
CA 72-4/TAG-72  
CA  
CA-242  
CA-549  
CAM  
CAR-3  
Cathepsin-D  
Chromogranin A and B  
Cluster 1 Antigen  
Cluster-5/5A Antigen  
CTA  
CU18  
DR-70  
DU-PAN-2  
Endometrial Bleeding Associated Factor  
Endostatin  
Epithelial Membrane Antigen  
Feulgen Hydrolysis  
Fibronectin  
FSH  
(1->3)-L-fucosyltransferase  
Gastrin-Releasing Peptide (GRP)  
GDCFP-15  
Glucagon  
Glycoamines  
H23  
Her-2

Human Carcinoma Antigen  
HPA  
HSP27  
Intermediate Filaments  
Cytokeratins/CK18/Cyfra 21-1  
Desmin  
Gliofibrillary Acid Protein  
Neurofilaments  
Vimentin  
KA  
Kinases  
KP16D3  
LAI  
Leukocyte Common Antigen  
Lewis Antigens  
Lysophosphatidic Acid (LPA)  
Ma 695/Ma  
MABDF3  
MAG  
ME1  
Minactivin  
MN/CA9  
MSA  
Mucin Cancer Antigen (MCA)  
Multiple Tumor Suppressor  
Myosin  
NEA-130  
NMP22  
OA-519  
Opioid Peptides  
P-glycoprotein  
Pancreatic Oncofetal Antigen (POA)  
Placental Lactogen  
PR92  
Proliferative Index, Ki-67  
Px  
RB Inactivation/Deletion  
Ret  
SCCL

Selectin  
Sialic Acid  
Sialyl SSEA-1/SLX  
SN10  
Somatostatin  
TA-90  
TAB A  
Tachykinin  
TAG  
TPS  
Troponin  
Tubulin  
VCAM  
VEGF  
Vill en

C. Cancer Diagnostic Testing Instrumentation Review and Market Needs

D. Current and Emerging Cancer Diagnostic Technologies

1. MONOCLONAL AND POLYCLONAL ANTIBODIES

2. IMMUNOASSAYS

3. MOLECULAR DIAGNOSTICS

4. CHROMOSOME ANALYSIS

a. Chronic Myelogenous Leukemia (CML)

b. Acute Myeloid Leukemia (AML)

c. Acute Lymphoblastic Leukemia (ALL)

d. Malignant Lymphomas Lymphoid Malignancies

e. Chronic Lymphocytic Leukemia (CLL)

f. Solid Cancers

g. Chromosomal Translocation and Oncogenes

5. ARTIFICIAL INTELLIGENCE

6. FLOW CYTOMETRY

7. TWO DIMENSIONAL GEL ELECTROPHORESIS (2-DGE)

8. BIOSENSORS

9. COMPETING/COMPLEMENTING TECHNOLOGIES

E. Personal Testing

**VIII. COUNTRY MARKET ANALYSES: TEST VOLUME AND SALES FORECASTS,  
SUPPLIER SHARES**

Bahrain

Iran  
Iraq  
Israel  
Jordan  
Kuwait  
Lebanon  
Oman  
Qatar  
Saudi Arabia  
United Arab Emirates

## **IX. COMPETITIVE PROFILES**

Abbott  
AdnaGen/Alere  
Agilent Technologies  
Applied Gene Technologies  
Arca Biopharma  
Beckman Coulter/Danaher  
Becton Dickinson  
Biomedical Diagnostics  
bioMerieux  
Bio-Rad  
CellSearch  
Cepheid  
Correlogic Systems/Vermillion  
Decode Genetics  
Diadexus  
Diagnocure  
Diasorin  
Eiken Chemical  
Elitech Group  
Enterix  
Enzo Biochem  
Epigenomics  
Exact Sciences  
Fujirebio  
Guided Therapeutics  
Hologic/Gen-Probe

Kreatech/Leica  
Kyowa Medex  
Mackay Life Sciences  
Myriad Genetics  
OncoLab  
Ortho-Clinical Diagnostics  
Panacea Pharmaceuticals  
Polartechnics  
Polymedco  
PreMD  
Qiagen  
Quest Diagnostics  
Radient Pharmaceuticals  
Roche  
Scienion  
Sequenom  
Siemens Healthcare  
Takara Bio  
Targeted Diagnostics & Therapeutics  
Tosoh  
Thermo  
Veridex  
Wako Pure Chemicals  
Wallac/PE  
Zila

## **X. APPENDIX: MAJOR UNIVERSITIES AND RESEARCH CENTERS DEVELOPING CANCER DIAGNOSTIC TECHNOLOGIES AND APPLICATIONS**

## List Of Tables

### LIST OF TABLES

Bahrain Cancer Diagnostic Volume Forecasts by Test  
Bahrain Cancer Diagnostics Sales Forecasts by Test  
Iran Cancer Diagnostic Volume Forecasts by Test  
Iran Cancer Diagnostics Sales Forecasts by Test  
Iraq Cancer Diagnostic Volume Forecasts by Test  
Iraq Cancer Diagnostics Sales Forecasts by Test  
Israel Cancer Diagnostic Volume Forecasts by Test  
Israel Cancer Diagnostics Sales Forecasts by Test  
Jordan Cancer Diagnostic Volume Forecasts by Test  
Jordan Cancer Diagnostics Sales Forecasts by Test  
Kuwait Cancer Diagnostic Volume Forecasts by Test  
Kuwait Cancer Diagnostics Sales Forecasts by Test  
Lebanon Cancer Diagnostic Volume Forecasts by Test  
Lebanon Cancer Diagnostics Sales Forecasts by Test  
Oman Cancer Diagnostic Volume Forecasts by Test  
Oman Cancer Diagnostics Sales Forecasts by Test  
Qatar Cancer Diagnostic Volume Forecasts by Test  
Qatar Cancer Diagnostics Sales Forecasts by Test  
Saudi Arabia Cancer Diagnostic Volume Forecasts by Test  
Saudi Arabia Cancer Diagnostics Sales Forecasts by Test  
United Arab Emirates Cancer Diagnostic Volume Forecasts by Test  
United Arab Emirates Cancer Diagnostics Sales Forecasts by Test Tumor Marker Classification  
Major Companies Developing or Marketing ACTH Tests  
Major Companies Developing or Marketing AFP Tests  
Major Companies Developing or Marketing Beta-2 Microglobulin Tests  
Major Companies Developing or Marketing CA 15-3/27.29 Tests  
Major Companies Developing or Marketing CA 19-9 Tests  
Major Companies Developing or Marketing CA 125 Tests  
Major Companies Developing or Marketing Calcitonin Tests  
Major Companies Developing or Marketing CEA Tests  
Major Companies Developing or Marketing Estrogen Receptor Tests  
Major Companies Developing or Marketing Progesterone Receptor Tests  
Major Companies Developing or Marketing Ferritin Tests  
Major Companies Developing or Marketing Gastrin Tests

Major Companies Developing or Marketing HCG Tests  
Major Companies Developing or Marketing Insulin Tests  
Major Companies Developing or Marketing NSE Tests  
Major Companies Developing or Marketing Occult Blood Tests  
Major Companies Developing or Marketing PAP Smear/HPV Tests  
Major Companies Developing or Marketing PAP Tests  
Major Companies Developing or Marketing PSA Tests  
Major Companies Developing or Marketing Lymphocyte Subclassification Tests  
Biochemical Markers Potential Applications In Cancer Diagnosis  
Oncogenes Potential Applications In Cancer Diagnosis  
Major Companies Developing or Marketing Oncogene Tests  
Growth Factors Potential Applications In Cancer Diagnosis  
Colony Stimulating Factors Potential Applications in Cancer Diagnosis  
Lymphokines Potential Applications in Cancer Diagnosis  
Immunohistochemical Stains Potential Applications in Cancer Diagnosis



## I would like to order

Product name: 2017 Middle East Tumor Marker Diagnostics Market: Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities

Product link: <https://marketpublishers.com/r/2960875FA43EN.html>

Price: US\$ 8,865.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/2960875FA43EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

